New immune drug IMA401 takes on Hard-to-Treat cancers

NCT ID NCT05359445

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 20 times

Summary

This early-phase trial tests a new drug called IMA401, which helps the immune system attack cancer cells. It is for adults with advanced solid tumors (like lung or head and neck cancer) that have come back or stopped responding to treatment. The study checks safety, the right dose, and whether adding another immune drug (pembrolizumab) works better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Charité Universitaetsmedizin Berlin KöR, Klinik fuer Haematologie und Onkologie

    Berlin, 12203, Germany

  • Goethe Universitaetsklinikum Frankfurt AöR, Medizinische Klinik II

    Frankfurt am Main, Hesse, 60590, Germany

  • Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III

    Chemnitz, Saxony, 09116, Germany

  • Klinikum Nuernberg, Klinik fuer Innere Medizin 5, Abteilung Onkologie/Haematologie

    Nuremberg, Bavaria, 90419, Germany

  • Klinikum rechts der Isar der TU Muenchen AöR, Klinik und Poliklinik fuer Innere Medizin III

    Munich, Bavaria, 81675, Germany

  • Marien Hospital Duesseldorf GmbH, Klinik fuer Onkologie/Haematologie und Palliativmedizin

    Düsseldorf, North Rhine-Westphalia, 40479, Germany

  • Medizinische Hochschule Hannover, Klinik fuer Haematologie, Haemostaseologie, Onkologie und Stammzelltransplantation

    Hanover, Lower Saxony, 30625, Germany

  • Thoraxklinik Heidelberg gGmbH, Studienzentrum Thoraxonkologie

    Heidelberg, Baden-Wurttemberg, 69126, Germany

  • Universitaet Leipzig, Universitaeres Krebszentrum Leipzig (UCCL)

    Leipzig, Saxony, 04103, Germany

  • Universitaetsklinikum C. - G. - Carus Dresden, Technische Universitaet Dresden AöR, NCT/UCC Early Clinical Trial Unit

    Dresden, Saxony, 01307, Germany

  • Universitaetsklinikum Erlangen AöR, Interdisciplinary Clinical Trial Unit with ECTU

    Erlangen, Bavaria, 91054, Germany

  • Universitaetsklinikum Freiburg, Zentralklinikum, Klinik fuer Innere Medizin I

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Universitaetsklinikum Heidelberg AöR, Nationales Zentrum fuer Tumorkrankheiten

    Heidelberg, Baden-Wurttemberg, 69120, Germany

  • Universitaetsklinikum Muenster AöR, Medizinische Klinik A

    Münster, North Rhine-Westphalia, 48149, Germany

  • Universitaetsklinikum Regensburg AöR, Klinik fuer Innere Medizin 3

    Regensburg, Bavaria, 93053, Germany

  • Universitaetsklinikum Schleswig- Holstein, Campus Kiel, Medizinische Klinik II Haematologie und Onkologie, Karl-Lennert Tumorzentrum

    Kiel, Schleswig-Holstein, 24105, Germany

  • Universitaetsklinikum Tuebingen AöR, Comprehensive Cancer Center Tuebingen

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Universitaetsklinikum Ulm AöR, ECTU-Early clinical Trials Unit Universitaetsklinikum Ulm Comprehensive Cancer Center Ulm_CCCU

    Ulm, Baden-Wurttemberg, 89081, Germany

  • Universitaetsklinikum Wuerzburg AöR, Interdisziplinaeres Studienzentrum mit ECTU

    Würzburg, Bavaria, 97078, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, III. Medizinische Klinik

    Mainz, Rhineland-Palatinate, 55131, Germany

  • Universitätsklinikum Bonn AöR, Medizinische Klinik IIII

    Bonn, North Rhine-Westphalia, 53127, Germany

Conditions

Explore the condition pages connected to this study.